Oceanpine Capital is a growth equity investment firm founded in 2016 and headquartered in Hong Kong, with additional offices in Beijing, Shanghai, and San Francisco. The firm specializes in partnering with entrepreneurs to nurture early to late-stage companies, focusing on sectors such as technology, media, telecommunications, healthcare, and advanced manufacturing. Oceanpine Capital aims to invest in private companies exhibiting rapid growth potential, while also exploring select opportunities in public companies. The firm emphasizes innovation in areas like artificial intelligence, semiconductors, 5G, cloud computing, and biotech, providing strategic resources and operational support to help build long-term, world-class businesses.
Xingchen New Energy develops new generation of ultra-high-performance all-vanadium flow energy storage system, fully covering electrolyte, stack and core R&D, manufacturing and production of components, energy storage systems and other products, and provide safer comprehensive energy storage solutions.
Blue Wave
Seed Round in 2023
Blue Wave is a producer of Industrial IoT and Internet of Vehicles chips.
Renxin Technology
Series A in 2023
Renxin Technology is an automotive chip design company. It provides competitive chip and system solutions for the industry and follows the evolution and development of automotive EE architecture.
Kuixin
Series A in 2023
Kuixin Technology specializes in the development and supply of integrated circuits aimed at addressing challenges related to computing power scaling and high-speed interconnection. The company offers a range of products, including USB, PCIe, SATA, SerDes, MIPI, DDR, HDMI, DP, and HBM chipsets. These components are designed for various applications across multiple sectors, including data centers, artificial intelligence, consumer electronics, automotive, and the Internet of Things (IoT). By focusing on these areas, Kuixin contributes to enhancing the performance and connectivity of modern technological systems.
SIRUI
Venture Round in 2022
SIRUI is an intelligent technology company that concentrates on the growth of strategic emerging industries and key core technologies such as semiconductor equipment and new display. Their products include atomic layer deposition coating equipment and thin-film electroluminescence displays. Its overseas technology research and development center will gradually conduct research, development, and industrialization of ALD and EL technology. It provides mature and leading ALD coating solutions for global customers in industrial coating applications such as semiconductors and optoelectronics, and it aids in the development of related industries such as semiconductors.
Qinghai Lihao
Series B in 2022
Qinghai Lihao specializes in the research, development, production, and sales of crystalline silicon, particularly for use in semiconductor materials. The company is dedicated to mass production of high-purity crystalline silicon, which supports the renewable energy sector and meets the demands of clients in the semiconductor industry. By focusing on process technology, Qinghai Lihao aims to advance its capabilities in the new energy business while ensuring the availability of essential materials for various applications.
Enflame Technology
Series C in 2022
Enflame, also known as Suiyuan Technology, specializes in developing advanced neural network solutions for artificial intelligence applications. The company focuses on creating high-end deep learning chips designed specifically for cloud data centers, optimizing them for AI training platforms. These chips feature a proprietary architecture that delivers significant computational power while ensuring high energy efficiency and low costs. Additionally, they are programmable and compatible with mainstream machine learning frameworks, making them suitable for a wide range of AI training and optimization tasks.
Huachen Core Light
Angel Round in 2022
Huachen Core Light is a semiconductor technology company that produces and manufactures optical communications and laser chips.
Aqronos
Series A in 2022
Aqronos specializes in advanced LiDAR technology designed for autonomous vehicles. The company develops innovative LiDAR sensors that enhance the vision capabilities of vehicles, transforming them into effective guardians on the road. By focusing on improving both autonomous driving and driver assistance systems, Aqronos aims to provide a safer driving experience for all users.
Shenzhen Shifeng
Series A in 2022
Shenzhen Shifeng offers industrial software, digital twin systems, and a simulation cloud service platform. The company serves marine engineering, aerospace, energy, electronic appliances, car traffic, and engineering manufacturing.
Clounix
Series A in 2022
Clounix is a software startup specializing in high-performance network chips and solutions, particularly focusing on application-specific integrated circuits (ASICs) designed for cloud networking. The company is dedicated to enhancing cloud networking technology through the development of ASICs that facilitate high-speed packet switching. Clounix supports super-internet companies, medium and large enterprises, and network operators in building next-generation networks and data centers. By creating advanced hardware and tailored software that align with cloud-native ecosystems, Clounix plays a crucial role in the evolution of modern networking infrastructure, catering to the needs of global Internet manufacturers and businesses seeking to improve their network capabilities.
Lisuan Technology
Angel Round in 2022
Liansu Technology is a software company specializing in the development of high-performance graphics rendering GPUs. The company focuses on creating domestically-made GPU chips using self-developed architecture and proprietary intellectual property. Liansu aims to serve the expansive domestic market for rendering GPUs, which is valued at 200 billion, by delivering high-performance graphics rendering solutions across various platforms, including devices, cloud computing, and automotive applications. Its products cater to diverse industries such as gaming, digital twins, the metaverse, virtual and augmented reality, ultra-high-definition video, and professional design. By leveraging its advanced technology, Liansu Technology provides partners with comprehensive software and hardware solutions tailored to meet the evolving needs of the digital economy.
OrthoGuard
Series A in 2021
OrthoGuard Physicians is a comprehensive orthopedic medical service organization based in China, focusing on the treatment and diagnosis of various musculoskeletal conditions, including joint, spine, ankle, and trauma injuries. The company emphasizes efficient management and innovative operational models to enhance patient care, facilitating quicker healing and improved recovery experiences. In addition to direct medical services, OrthoGuard is involved in hospital management, rehabilitation services, and education and training initiatives. The organization also engages in supply chain management and the establishment of demonstration diagnosis and treatment centers, aiming to create a reputable and innovative medical group in the orthopedic field. Through these efforts, OrthoGuard seeks to leverage its extensive resources and expertise to advance orthopedic healthcare in China.
Yuchuang Semiconductor
Series A in 2021
Erised Semiconductor is a circuit designer and manufacturer that provides users with display driver and power management chips. The applications can be found in radiofrequency applications, discrete devices, and other products.
Chipone Technology
Series E in 2021
Chipone Technology is a prominent chip design company that specializes in display solutions, positioning itself as a competitive player in the global market. The company's product portfolio includes a comprehensive range of display chips, such as TDDI (display driver and touch integrated chip), medium and large size display driver chips, OLED display chips, power management chips, LED display driver chips, timing control chips, fingerprint recognition chips, and touch control chips, including silicon-based OLED chips. Chipone's innovative technologies are utilized across various applications, including televisions, monitors, notebooks, tablets, smartphones, and wearable devices. The company serves a diverse clientele, comprising leading global panel manufacturers, top-tier domestic mobile device brands, and renowned LED display manufacturers.
MingMed
Series A in 2021
MingMed is a Chinese pharmaceutical company focused on independent drug research and development, with a diverse product pipeline that includes ophthalmic drugs, small molecule immune drugs, and cell therapies utilizing gene editing. The company's offerings extend to recombinant protein botulinum toxin, tumor immune drugs, and immunotherapy for pets. MingMed is dedicated to producing innovative solutions across various fields, including ophthalmology, medical aesthetics, and veterinary medicine, with several of its promising drug candidates having reached the clinical stage. The company's commitment to developing First-in-Class innovative drugs positions it competitively in the global pharmaceutical market.
SVOLT
Series B in 2021
SVOLT manufacturer of electric batteries. They specialize in the manufacturing of automotive power batteries and energy storage systems. Their market applications include passenger cars, commercial vehicles, energy storage, and light power solutions. Their products include batteries and energy storage batterie. They provide users with energy vehicle charging piles, batteries recycling, and solutions.
Tongshu Gene
Series C in 2021
Tongshu Gene is a high-tech enterprise specializing in tumor precision medicine. The company offers gene testing services and develops diagnostic molecular pathology projects, alongside ctDNA precision detection systems that utilize high-throughput gene sequencing technology and biological information analysis. These innovations enable clinicians to access consulting services related to precision medication, efficacy monitoring, postoperative recurrence tracking, as well as risk prediction and early detection of tumors.
Stemirna
Venture Round in 2021
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.
Weilong Foods
Series A in 2021
Weilong Foods is a prominent snack food brand based in Luohe, Henan Province, China, specializing in the production and sale of spicy snack foods. Founded in 1999 by Liu Weiping and Liu Fuping, the company operates through various business units categorized into three main segments: seasoned flour products, vegetable products, and bean-based and other products. The seasoned flour products, which include items like Big Latiao and Spicy Hot Stick, generate the majority of the company's revenue. In addition to these, Weilong Foods also offers products such as Konjac Shuang and Soft Tofu Skin, catering to a diverse consumer base within the Chinese market.
Hepagene Therapeutics
Series B in 2021
Hepagene Therapeutics is focused on developing innovative treatments for liver diseases. The company engages in research and development efforts aimed at addressing conditions such as non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection, and liver cancer. By concentrating on these critical areas, Hepagene Therapeutics seeks to provide effective pharmaceutical solutions that can significantly improve patient outcomes in the realm of liver health.
TechnoDerma Medicines
Series A in 2021
TechnoDerma Medicines is a private clinical-stage biopharmaceutical company dedicated to developing innovative therapies for various skin diseases. Its research and development efforts focus on small molecular drugs aimed at treating conditions such as androgenetic alopecia, atopic dermatitis, psoriasis, lupus erythematosus, and scars. The company's goal is to provide patients with safe and effective treatment options, addressing unmet medical needs in the dermatological field.
Immune-Onc Therapeutics
Series B in 2021
Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.
JuLive.com
Series C in 2021
Julive is a new house transaction service platform.
LakeShore Biopharma
Series B in 2021
Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.
Teon Therapeutics
Series A in 2021
Teon Therapeutics is a clinical-stage biopharmaceutical company based in Redwood, California, founded in 2018. The company is focused on developing small molecule drugs aimed at cancer immunotherapy as well as addressing cardiovascular and metabolic diseases. Teon Therapeutics specializes in creating single-target small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways within the tumor microenvironment. Its lead program involves an A2BR-specific antagonist, which is set to enter Phase 1b trials. By combining metabolic and GPCR immune checkpoint inhibitors, Teon aims to enhance the efficacy of immunotherapies, thereby improving long-term outcomes for cancer patients.
Clover Biopharmaceuticals
Series C in 2021
Clover Biopharmaceuticals is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative biologic therapies primarily targeting oncology and autoimmune diseases. The company employs its proprietary Trimer-Tag technology platform to create novel biologics that focus on trimerization-dependent pathways. In addition to its therapeutic efforts, Clover is also engaged in the development of select biosimilars, utilizing its in-house cGMP biomanufacturing capabilities. The company aims to address unmet medical needs in both infectious diseases and cancer through its advanced vaccine and therapeutic candidates.
Sinovent
Venture Round in 2020
Sinovent Inc., established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and additional offices in Beijing, China, and Boston, U.S.A. The company specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in development, leveraging its expertise in science, management, and finance, and commitment to global standard excellence through its advanced biotechnology platform.
XtalPi Technology
Series C in 2020
XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.
Guangzhou Creative Biosciences
Series C in 2020
Guangzhou Creative Biosciences, established in Guangzhou, China, is a biomedical technology company specializing in the research, development, production, and sales of diagnostic kits for early cancer detection. Its primary focus is on colorectal cancer, offering non-invasive fecal screening kits that detect genetic abnormalities in feces, aiding practitioners in identifying early intestinal cancer lesions. Additionally, the company develops and sells diagnostic kits and equipment for lung cancer.
Triumvira Immunologics
Series A in 2020
Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.
Sinovent
Series C in 2020
Sinovent Inc., established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and additional offices in Beijing, China, and Boston, U.S.A. The company specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in development, leveraging its expertise in science, management, and finance, and commitment to global standard excellence through its advanced biotechnology platform.
hireEZ
Series B in 2020
hireEZ is an AI-powered outbound recruiting platform designed to assist recruiters in proactively connecting with potential job candidates. The platform aims to empower organizations to transition from traditional inbound recruiting methods to a more strategic outbound approach, ultimately helping them achieve their hiring goals and build diverse workplaces. By providing market insights and enhancing visibility of talent, hireEZ enables recruiters to navigate the competitive talent acquisition landscape more effectively. The company's mission is to simplify the recruitment process, allowing businesses to identify and hire the right individuals to meet their workforce needs.
Enflame Technology
Series B in 2020
Enflame, also known as Suiyuan Technology, specializes in developing advanced neural network solutions for artificial intelligence applications. The company focuses on creating high-end deep learning chips designed specifically for cloud data centers, optimizing them for AI training platforms. These chips feature a proprietary architecture that delivers significant computational power while ensuring high energy efficiency and low costs. Additionally, they are programmable and compatible with mainstream machine learning frameworks, making them suitable for a wide range of AI training and optimization tasks.
Apexigen
Series C in 2020
Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, dedicated to the discovery and development of antibody therapeutics for cancer treatment. The company focuses on creating innovative immuno-oncology products that leverage the patient's immune system to effectively combat and eliminate cancer. Apexigen's therapeutic pipeline includes several candidates such as APX005M and APX201 for immuno-oncology, alongside APX003 and TRK-950 for oncology, as well as APX001 for inflammation and APX003 for ocular diseases. Additionally, the company has developed the APXiMAB platform, which facilitates the discovery of antibodies targeting novel immune system components. Founded in 2010, Apexigen aims to advance next-generation therapies that address significant unmet needs in cancer treatment.
Zshield
Series B in 2019
Zshield Inc. is a Beijing-based company specializing in cyberspace data security and big data business risk management. Established in 2014, it is recognized as the first high-tech firm in China to leverage big data technologies in addressing emerging information security vulnerabilities. Zshield develops advanced integrated information security solutions that utilize lightweight virtualization, deep learning, and big data analysis to provide effective monitoring of server and terminal security. Its offerings include a comprehensive information security platform and the AndunTM ZS-ISP, which supports both government and enterprise clients in navigating the complexities of modern computing environments, including cloud computing and mobile applications. As traditional security measures struggle to cope with new threats, Zshield's innovative approach aims to fortify businesses against the evolving landscape of information security challenges.
Ansun Biopharma
Series B in 2019
Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.
Enflame Technology
Series A in 2019
Enflame, also known as Suiyuan Technology, specializes in developing advanced neural network solutions for artificial intelligence applications. The company focuses on creating high-end deep learning chips designed specifically for cloud data centers, optimizing them for AI training platforms. These chips feature a proprietary architecture that delivers significant computational power while ensuring high energy efficiency and low costs. Additionally, they are programmable and compatible with mainstream machine learning frameworks, making them suitable for a wide range of AI training and optimization tasks.
Horizon Robotics
Series B in 2019
Horizon Robotics is a prominent provider of advanced driver assistance systems (ADAS) and autonomous driving solutions specifically designed for passenger vehicles. The company develops proprietary software and hardware that integrate advanced algorithms and specialized processing capabilities. These technologies form the foundation for enhanced driving automation, aiming to improve both safety and the overall experience for drivers and passengers. By focusing on innovative solutions, Horizon Robotics plays a key role in the evolution of assisted and autonomous driving.
Inspirna
Series C in 2018
Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.
51Zhaoyou.com
Series C in 2018
51Zhaoyou.com operates as a B2B ecommerce platform dedicated to the petroleum industry in China. It facilitates transactions through an online marketplace, offering comprehensive services including fuel trading, logistics management, and financial solutions tailored for its client base comprising leading logistics companies.
Tiger Brokers
Series C in 2018
Tiger Brokers, established in 2014, is a leading online brokerage firm specializing in facilitating global investments for Chinese investors. The company's platform enables users to trade equities and other financial instruments across multiple exchanges worldwide. Tiger Brokers offers comprehensive services including order placement and execution, margin financing, account management, investor education, community discussion forums, and customer support.
Ansun Biopharma
Series A in 2018
Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.